Abstract
Provided herein are novel ergoline compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mood disorders such as depressive disorders and bipolar disorders, and processes for preparing such compounds.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have